AustCancer subsidiary signs distribution deal

By Renate Krelle
Tuesday, 06 July, 2004

ACT US, the US subsidiary of oncology specialist Australian Cancer Technology ("AustCancer") (ASX: ACU) has signed a distribution deal for its revisys range of nutritional supplements.

Under the deal, wholesale drug cooperative Rochester Drug Cooperative will stock revisys in more than eight hundred community retail pharmacies long-term care pharmacies and home health care stores in New York State, Pennsylvania and New Jersey.

$780m Sydney Biomedical Accelerator gains its founding Executive Director

Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...

Portable point-of-care test detects four common STIs in under an hour

Australian researchers have developed a portable point-of-care test that detects four common...

AusBiotech and Proto Axiom partner on investor-focused life sciences programs

AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...

Content from other channels on our network

ARENA awards $13m for industrial decarbonisation

NVIDIA working with global robotics companies on physical AI

Physical AI set to transform industrial operations: report

Queensland announces $200m for sustainable energy in the North West

Industry Growth Program supports 13 new commercialisation projects

Ahpra launches the National Scheme Strategy 2031

The Agency establishes National Clinical Governance Committee for Digital Health

'No evidence' of medicinal cannabis effectiveness treating anxiety, depression or PTSD

COVID-19 training fail lands residential aged care provider $150K fine

AdPha partners with Therapeutic Guidelines to deliver obesity clinical guidance

New fund drives waste sector innovation

Epson on CDP 'A List'

APCO and SPSA partner on soft plastics stewardship

Partnership creates national manufacturing roadmap

$2.1bn battery recycling sector critical to Australia's sovereign capability